Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading under the ticker LGST, is a clinical-stage biopharmaceutical company operating in the life sciences and biotechnology sector, with a platform focused on T-cell receptor-based immunotherapy targeting infectious diseases and oncology indications. The company reached the public markets via a SPAC transaction and filed a Form 10-Q with the SEC on May 17, 2022, under accession number 0001410578-22-001755, marking an early period of its public reporting history. The filing reflects the company's operational and financial status as it advanced its proprietary immunotherapy pipeline. Investors and analysts tracking SPAC-related biotech names can access full deal history, sponsor details, and filing timelines for Tevogen Bio and hundreds of other transactions by signing up for SpacDesk.